BioMarin flags USD 283 million charge. BioMarin stock loses 1.83 percent.
Published on 10/07/2026 at 04:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
BioMarin Pharmaceutical (US09061G1013) disclosed a USD 283 million in-process research and development expense for the third quarter of 2026 on October 6, 2026, according to GuruFocus. The charge is expected to reduce both GAAP and non-GAAP diluted earnings per share by USD 1.50, putting pipeline investment directly against near-term profitability.
Revenue growth meets a cost charge
BioMarin generated USD 989.70 million in revenue in the second quarter of 2026, up 20.00 percent from the same quarter a year earlier, Zacks reported on October 2, 2026. The quarter's diluted earnings per share were USD 0.23, while consolidated net income was USD 44.76 million.
VOXZOGO contributed USD 253 million of sales in the quarter, a 14.00 percent year-over-year increase, according to Zacks. That commercial growth gives BioMarin a counterweight to the USD 283 million research expense, but the charge is material against quarterly net income of USD 44.76 million.
Guidance moves higher for 2026
BioMarin raised its full-year 2026 total revenue guidance to USD 3.875 billion to USD 3.925 billion from USD 3.825 billion to USD 3.925 billion, according to Zacks. The company also lifted adjusted diluted earnings-per-share guidance to USD 4.90 to USD 5.10 from USD 4.85 to USD 5.05.
The updated outlook makes the Amicus portfolio central to the investment case. The second-quarter figures show the acquisition adding sales, while the research charge shows that BioMarin is still spending heavily to extend its rare-disease pipeline. The combination creates a wider operating bridge between current products and future launches.
Stock remains below its recent range
BioMarin stock was last at EUR 55.66 on Tradegate on September 18, 2026 at 8:02 p.m. CEST, down 1.83 percent versus the Tradegate close of EUR 56.70 on September 17, 2026. The primary listing is Nasdaq, where the finance quote showed USD 56.22 at 4:00 p.m. ET on October 6, 2026, versus a USD 49.26 to USD 70.98 52-week range.
The further course of trading is shown by the continuously updated real-time quote of BioMarin stock.
BioMarin stock facts
- Company: BioMarin Pharmaceutical Inc.
- ISIN: US09061G1013
- Ticker: BMRN
- Primary exchange: Nasdaq
- Price substitute Tradegate (as of September 18, 2026, 8:02 p.m. CEST): EUR 55.66
- Change versus Tradegate close: minus 1.83 percent
- Tradegate close (September 17, 2026): EUR 56.70
- Market capitalization: USD 10.9 billion (as of October 6, 2026)
- 52-week range: USD 49.26-70.98 (as of October 6, 2026)
- Sector / Industry: Healthcare / Biotechnology
